IP Library › Granted Patent US 7,569,555
Granted Patent B2
US 7,569,555 · App. 11/079,886 · Granted Aug 4, 2009

Method for stimulating the immune, inflammatory or neuroprotective response

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,569,555
App. No.
11/079,886
Granted
Aug 4, 2009
Kind
B2
Abstract

Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic dinucleotide analogue thereof, also has neuroprotective properties for use as a neuroprotective agent to inhibit, treat, or ameliorate the effects of injuries, diseases, disorders or conditions that result in neurodegeneration.

Claims (17)

1. A method for modulating immune or inflammatory response in a patient, comprising administering an effective amount of cyclic di-GMP or a cyclic dinucleotide analogue thereof to a patient in need thereof to modulate the immune or inflammatory response.

2. The method of claim 1 , comprising administering an effective amount of cyclic di-GMP or a cyclic dinucleotide analogue thereof to a patient in need thereof to stimulate or enhance the immune or inflammatory response in the patient.

3. The method of claim 2 , wherein an effective amount of cyclic di-GMP is administered to the patient in need thereof.

4. The method of claim 2 , wherein an effective amount of a cyclic dinucleotide analogue is administered to the patient in need thereof.

5. The method of claim 4 , wherein said cyclic dinucleotide analogue thereof is selected from the group consisting of cyclic dinucleotide compounds (I)-(XX)

6. The method of claim 2 , wherein the immune response stimulated or enhanced includes a Th1 oriented immune response.

7. The method of claim 2 , which enhances immune response to a vaccine, wherein an effective amount of a vaccine or antigen is administered to the patient in need thereof in combination with an effective amount of cyclic di-GMP or a cyclic dinucleotide analogue thereof.

8. The method of claim 7 , wherein the immune response is a cellular response.

9. The method of claim 7 , wherein the vaccine is selected from the group consisting of a protein vaccine, a polysaccharide vaccine, a DNA vaccine, a live attenuated vaccine, and a killed vaccine.

10. A method for inhibiting neuronal degeneration, comprising administering to a patient in need thereof an effective amount of cyclic di-GMP or a cyclic dinucleotide analogue thereof to inhibit neuronal degeneration in the patient.

11. The method of claim 10 , wherein an effective amount of cyclic di-GMP is administered to the patient in need thereof.

12. The method of claim 10 , wherein an effective amount of a cyclic dinucleotide analogue is administered to the patient in need thereof.

13. The method of claim 12 , wherein said cyclic dinucleotide analogue thereof is selected from the group consisting of cyclic dinucleotide compounds (I)-(XX)

14. The method of claim 1 , comprising administering an effective amount of cyclic di-GMP or a cyclic dinucleotide analogue thereof to a patient in need thereof to inhibit an allergic reaction.

15. The method of claim 14 , wherein an effective amount of cyclic di-GMP is administrated to the patient in need thereof.

16. The method of claim 14 , wherein an effective amount of a cyclic dinucleotide analogue of cyclic di-GMP is administered to the patient in need thereof.

17. The method of claim 16 , wherein said cyclic dinucleotide analogue is selected from the group consisting of cyclic dinucleotide compounds (I)-(XX)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2012
From: KARAOLIS, DAVID
To: KARAGEN PHARMACEUTICALS
Reel/Frame 028045/0533 →
Continuity (3)
Provisional Application 6056369200 · Apr 20, 2004
Provisional Application 6055272100 · Mar 15, 2004
Related Publication 20060040887A1 · Feb 23, 2006